CN102170881A - 用于肾脏细胞癌的治疗的3,3’,4,4’-四羟基-2,2’-联吡啶-n,n’-二氧化物 - Google Patents
用于肾脏细胞癌的治疗的3,3’,4,4’-四羟基-2,2’-联吡啶-n,n’-二氧化物 Download PDFInfo
- Publication number
- CN102170881A CN102170881A CN2009801393664A CN200980139366A CN102170881A CN 102170881 A CN102170881 A CN 102170881A CN 2009801393664 A CN2009801393664 A CN 2009801393664A CN 200980139366 A CN200980139366 A CN 200980139366A CN 102170881 A CN102170881 A CN 102170881A
- Authority
- CN
- China
- Prior art keywords
- chemical compound
- pharmaceutically acceptable
- formula
- toxin
- austria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC*/*(/C)=C(\C(CO)[O-])/C(C(O)=C)[N+](C)O Chemical compound CC*/*(/C)=C(\C(CO)[O-])/C(C(O)=C)[N+](C)O 0.000 description 2
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (18)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510353115.3A CN105147683B (zh) | 2008-10-06 | 2009-10-06 | 用于肾脏细胞癌的治疗的3,3',4,4'-四羟基-2,2'-联吡啶-n,n'-二氧化物 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19531208P | 2008-10-06 | 2008-10-06 | |
US61/195,312 | 2008-10-06 | ||
US12/586,849 US8053430B2 (en) | 2008-10-06 | 2009-09-29 | Treatment of renal cell carcinoma |
US12/586,849 | 2009-09-29 | ||
PCT/EP2009/062976 WO2010040750A1 (en) | 2008-10-06 | 2009-10-06 | 3, 3', 4, 4' -tetrahydroxy-2, 2' -bipyridine-n, n' -dioxides for the treatment of renal cell carcinoma |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510353115.3A Division CN105147683B (zh) | 2008-10-06 | 2009-10-06 | 用于肾脏细胞癌的治疗的3,3',4,4'-四羟基-2,2'-联吡啶-n,n'-二氧化物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102170881A true CN102170881A (zh) | 2011-08-31 |
CN102170881B CN102170881B (zh) | 2015-07-22 |
Family
ID=41395600
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510353115.3A Active CN105147683B (zh) | 2008-10-06 | 2009-10-06 | 用于肾脏细胞癌的治疗的3,3',4,4'-四羟基-2,2'-联吡啶-n,n'-二氧化物 |
CN200980139366.4A Active CN102170881B (zh) | 2008-10-06 | 2009-10-06 | 用于肾脏细胞癌的治疗的3,3’,4,4’-四羟基-2,2’-联吡啶-n,n’-二氧化物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510353115.3A Active CN105147683B (zh) | 2008-10-06 | 2009-10-06 | 用于肾脏细胞癌的治疗的3,3',4,4'-四羟基-2,2'-联吡啶-n,n'-二氧化物 |
Country Status (12)
Country | Link |
---|---|
US (2) | US8053430B2 (zh) |
EP (1) | EP2349268B1 (zh) |
JP (1) | JP5340393B2 (zh) |
KR (1) | KR101678702B1 (zh) |
CN (2) | CN105147683B (zh) |
CA (1) | CA2736322C (zh) |
DK (1) | DK2349268T3 (zh) |
ES (1) | ES2401671T3 (zh) |
HK (2) | HK1161116A1 (zh) |
PL (1) | PL2349268T3 (zh) |
PT (1) | PT2349268E (zh) |
WO (1) | WO2010040750A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102985088A (zh) * | 2010-04-01 | 2013-03-20 | 奥科瑞纳有限公司 | 肾细胞癌的改进治疗 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201103578D0 (en) * | 2011-03-02 | 2011-04-13 | Sabrepharm Ltd | Dipyridinium derivatives |
CN105450495B (zh) * | 2014-09-18 | 2018-09-21 | 中国电信股份有限公司 | 用于重新建立安全通信通道的方法、装置和系统 |
WO2024002909A1 (en) | 2022-07-01 | 2024-01-04 | Oncorena Ab | Orellanine formulation |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4713352A (en) | 1981-08-31 | 1987-12-15 | Sloan-Kettering Institute For Cancer Reseach | Monoclonal antibody panel for early diagnosis and therapy of renal carcinoma |
US6403373B1 (en) | 1997-10-10 | 2002-06-11 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules associated with colon, renal, and stomach cancer and methods of using these |
US6440663B1 (en) | 1998-10-05 | 2002-08-27 | Ludwig Institute For Cancer Research | Renal cancer associated antigens and uses therefor |
DE60020442T2 (de) | 1999-04-08 | 2006-05-04 | Schering Corp. | Behandlung von Nierenzellen-Karzinom |
CN1359941A (zh) | 2000-12-20 | 2002-07-24 | 上海博德基因开发有限公司 | 一种新的多肽——人肾癌rage4抗原11.44和编码这种多肽的多核苷酸 |
RU2188026C1 (ru) | 2001-01-12 | 2002-08-27 | Ростовский научно-исследовательский онкологический институт | Способ лечения рака почки |
EP1712234B1 (en) | 2001-09-12 | 2009-01-28 | Novartis AG | Use of 4-Pyridylmethylphthalazines for Renal Cancer Treatment |
WO2004002526A1 (en) | 2002-07-01 | 2004-01-08 | Wilex Ag | Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas |
DE10307928A1 (de) | 2003-02-25 | 2004-09-16 | Faustus Forschungs Cie. Translational Cancer Research Gmbh | Verwendung von 1-(2-Chlorethyl)-1-nitroso-3-(2-hydroxyethyl)-urea zur Behandlung von Pankreaskarzinomen, Weichteilsarkomen, Hodentumoren, Lymphomen, Thymomen, Wilms Tumoren, Nierenkarzinomen, Melanomen, Lungentumoren, intracerebralen Metastasen, Tumoren im Kopf- und Halsbereich, und Mamma-Karzinomen |
WO2006044779A1 (en) | 2004-10-14 | 2006-04-27 | Northwestern University | Detection and treatment of renal cancer |
AU2005337169B2 (en) | 2005-10-14 | 2011-09-22 | Governement Of The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Treating or preventing renal cancer using a dimethane sulfonate |
EP1957115B8 (en) | 2005-11-10 | 2014-03-05 | Celldex Therapeutics, Inc. | Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen |
-
2009
- 2009-09-29 US US12/586,849 patent/US8053430B2/en active Active
- 2009-10-06 KR KR1020117007204A patent/KR101678702B1/ko active IP Right Grant
- 2009-10-06 CA CA2736322A patent/CA2736322C/en active Active
- 2009-10-06 CN CN201510353115.3A patent/CN105147683B/zh active Active
- 2009-10-06 JP JP2011529583A patent/JP5340393B2/ja active Active
- 2009-10-06 PL PL09783788T patent/PL2349268T3/pl unknown
- 2009-10-06 CN CN200980139366.4A patent/CN102170881B/zh active Active
- 2009-10-06 ES ES09783788T patent/ES2401671T3/es active Active
- 2009-10-06 WO PCT/EP2009/062976 patent/WO2010040750A1/en active Application Filing
- 2009-10-06 EP EP09783788A patent/EP2349268B1/en active Active
- 2009-10-06 DK DK09783788.4T patent/DK2349268T3/da active
- 2009-10-06 PT PT97837884T patent/PT2349268E/pt unknown
-
2011
- 2011-09-21 US US13/200,222 patent/US8349823B2/en active Active
-
2012
- 2012-02-24 HK HK12101894.1A patent/HK1161116A1/zh unknown
-
2016
- 2016-06-14 HK HK16106846.5A patent/HK1218857A1/zh unknown
Non-Patent Citations (3)
Title |
---|
C.HEUFLER, ET AL.: "investigations on the mode of action of the fungus toxin orellanine on renal cell cultures", 《AGENTS AND ACTIONS》 * |
CHRISTIANE RUEDL, ET AL.: "differential inhibitory action of the fungal toxin orellanine on alkaline phosphatase isoenzymes", 《BIOCHIMICA ET BIOPHYSICA ACTA》 * |
龚庆芳,等: "蘑菇毒素及其中毒治疗(II)-奥来毒素", 《实用预防医学》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102985088A (zh) * | 2010-04-01 | 2013-03-20 | 奥科瑞纳有限公司 | 肾细胞癌的改进治疗 |
Also Published As
Publication number | Publication date |
---|---|
KR20110073486A (ko) | 2011-06-29 |
CA2736322C (en) | 2017-01-10 |
EP2349268A1 (en) | 2011-08-03 |
US20120077846A1 (en) | 2012-03-29 |
CN105147683A (zh) | 2015-12-16 |
WO2010040750A1 (en) | 2010-04-15 |
US20100152243A1 (en) | 2010-06-17 |
EP2349268B1 (en) | 2013-01-16 |
CN102170881B (zh) | 2015-07-22 |
CN105147683B (zh) | 2019-01-22 |
KR101678702B1 (ko) | 2016-11-22 |
CA2736322A1 (en) | 2010-04-15 |
US8349823B2 (en) | 2013-01-08 |
DK2349268T3 (da) | 2013-04-15 |
PL2349268T3 (pl) | 2013-06-28 |
US8053430B2 (en) | 2011-11-08 |
HK1161116A1 (zh) | 2012-08-24 |
PT2349268E (pt) | 2013-04-02 |
ES2401671T3 (es) | 2013-04-23 |
JP5340393B2 (ja) | 2013-11-13 |
HK1218857A1 (zh) | 2017-03-17 |
JP2012504584A (ja) | 2012-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105338977B (zh) | 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途 | |
CN104363913B (zh) | Cdk8/cdk19选择性抑制剂及其在癌症的抗转移和化学预防方法中的用途 | |
CN102170881B (zh) | 用于肾脏细胞癌的治疗的3,3’,4,4’-四羟基-2,2’-联吡啶-n,n’-二氧化物 | |
JP2023179452A (ja) | 癌の転移抑制および治療用組成物 | |
KR101901001B1 (ko) | PPAR-β 길항제를 포함하는 항암 효과 증진용 약학적 조성물 | |
KR102509715B1 (ko) | 암의 전이 억제 및 치료용 조성물 | |
CN102985088B (zh) | 肾细胞癌的改进治疗 | |
CN111617081B (zh) | 一种取代丁烯酰胺联合mTOR抑制剂的药物组合物及其用途 | |
CN110290787B (zh) | 用于抑制癌的转移及治疗癌的组合物 | |
TW201306833A (zh) | 包含康布列塔司他汀(combretastatins)族衍生物及西妥昔單抗(cetuximab)之組合 | |
CN108503676A (zh) | 用于癌症治疗的果糖类似物及其组合物 | |
AU2018239428A1 (en) | Encapsulated cells producing cytochrome P450 and methods of use thereof | |
CN105560224A (zh) | 盐霉素在制备抑制血管新生药物中的应用 | |
CN115835864A (zh) | 包含3-酮脂酰辅酶a硫解酶抑制剂以及肉碱酰基肉碱载体抑制剂的用于预防或治疗癌症的药物组合物 | |
CN103933039B (zh) | 一种含水飞蓟宾和索拉非尼的药物组合物及其应用 | |
Saif et al. | Gastrointestinal bleeding associated with concurrent capecitabine and radiotherapy in patients with pancreatic cancer | |
Fujitani et al. | Feasibility study of S-1 plus weekly docetaxel combined with concurrent radiotherapy in advanced gastric cancer refractory to first-line chemotherapy | |
Bruckner | Adjuvant therapy for prevention of liver metastases | |
Sheffield | The Role of Positron-emission Tomography in the Management of Recurrent and Metastatic Colorectal Cancer | |
CN102675370A (zh) | 一种用于治疗癌症的新化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: AUCODES REINA CO., LTD. Free format text: FORMER OWNER: JENNY NYSTROEM Effective date: 20120510 Free format text: FORMER OWNER: BOUVARD LISA ULF NILSSON HARALDSSON BOERJE Effective date: 20120510 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20120510 Address after: Goteborg - Dahl Boggs Eric of Sweden S-41126 gueutin street 11A Applicant after: Oncorena AB Address before: Gothenburg Applicant before: Nystroem Jenny Co-applicant before: Buvall Lisa Co-applicant before: Nilsson Ulf Co-applicant before: Haraldsson Boerje |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1161116 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1161116 Country of ref document: HK |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1161116 Country of ref document: HK |